Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 17/20 | 0.58 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490350 | 1.00 | CXCR2 (0.58) | CXCR2CXCR1HTR1BCX3CR1LMNA | |
| SCHEMBL490114 | 0.87 | CXCR2 (0.58) | CXCR2CXCR1HTR1BCX3CR1LMNA | |
| SCHEMBL489549 | 0.87 | CXCR2 (0.79) | CXCR2CXCR1HTR1BCX3CR1 | |
| SCHEMBL489550 | 0.87 | CXCR2 (0.79) | CXCR2CXCR1HTR1BCX3CR1 | |
| SCHEMBL490113 | 0.87 | CXCR2 (0.58) | CXCR2CXCR1HTR1BCX3CR1LMNA | |
| SCHEMBL489576 | 0.85 | CXCR2 (0.75) | CXCR2CXCR1HTR1BCX3CR1LMNA | |
| SCHEMBL490272 | 0.85 | CXCR2 (0.65) | CXCR2CXCR1HTR1BCX3CR1 | |
| SCHEMBL489669 | 0.83 | CXCR2 (0.63) | CXCR2CXCR1HTR1BCX3CR1KMT2A | |
| SCHEMBL489780 | 0.83 | CXCR2 (0.75) | CXCR2CXCR1 | |
| SCHEMBL1487200 | 0.82 | CXCR2 (0.58) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527051-B1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8106063-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| US-7582644-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| CN-100345829-C | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| CN-1681795-A | Pyrimidyl sulfonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ACKR3, GPR17, CCL11 | CXCR2 38/4885CXCR1 9/4885HTR1B 2017/4885 |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ACKR3, GPR17, CCL11 | CXCR2 38/4885CXCR1 9/4885HTR1B 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.